^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ianalumab (VAY736)

    i
    Other names: VAY736, NOV-5, VAY-736, VAY 736, NOV5, NOV 5
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    BAFF-R inhibitor
    Related drugs:
    Associations

    News

    Trials
    8d
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2030 --> Mar 2030 | Trial primary completion date: Dec 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    18d
    NEPTUNUS-Ext: A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (clinicaltrials.gov)
    P3, N=612, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2030 --> Apr 2033 | Trial primary completion date: Aug 2028 --> Apr 2033
    Trial completion date • Trial primary completion date
    |
    ianalumab (VAY736)
    21d
    VAY RE-HIT: Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab (clinicaltrials.gov)
    P2, N=60, Recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    ianalumab (VAY736)
    21d
    VAYHIA: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P3, N=90, Active, not recruiting, Novartis Pharmaceuticals | N=35 --> 90 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    ianalumab (VAY736)
    23d
    SIRIUS-LN: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (clinicaltrials.gov)
    P3, N=462, Recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2030 --> Feb 2031
    Trial completion date
    |
    ianalumab (VAY736)
    1m
    VAYHIA: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P3, N=90, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ianalumab (VAY736)
    2ms
    AMBER: ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (clinicaltrials.gov)
    P2/3, N=68, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    ianalumab (VAY736)
    2ms
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    2ms
    CVAY736Q12202B: A phase 2 study of ianalumab in adults with primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who have previously benefited from ianalumab. (2024-518231-11-00)
    P1/2, N=65, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ianalumab (VAY736)
    2ms
    VAYHIA: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P3, N=90, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2029 --> Dec 2028
    Trial completion date
    |
    ianalumab (VAY736)
    2ms
    Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. (clinicaltrials.gov)
    P2, N=21, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2026
    Trial completion • Trial completion date
    |
    ianalumab (VAY736)
    2ms
    Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) (clinicaltrials.gov)
    P3, N=285, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)
    |
    ianalumab (VAY736)